Definitive Contract HHSN261200622017C
Award Date 9/1/06
Potential Completion Date 8/31/08
Potential Value $1.5M
Funding Federal Agency
Not listed Contracting Federal Agency
Ultimate Awardee
Not listed NAICS Category
Not listed PSC Category
Set-Aside Type
Total Small Business
Federal Contract Vehicle
- Not listed
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Cleveland, OH 44106, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed Similar Awards
- This is a definitive, cost-no-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Cleveland Biolabs, Inc. to develop a therapy for hematopoietic syndrome resulting from acute radiation exposure. The contract, which does not have a set-aside designation, has a ceiling value of $21,956,799.00 and an ultimate completion date of October 15, 2010. As the prime contractor, Cleveland Biolabs, Inc. is responsible for delivering the...
- This is a cost-plus-fixed-fee definitive contract awarded by the Defense Health Agency, a defense agency, to Cleveland Biolabs, Inc. The contract has a ceiling value of $3,558,603.15 and a period of performance through August 31, 2020. The contract was not set aside for any socioeconomic program. The purpose of the contract is not explicitly stated, but based on the agency and the location of performance in Buffalo, New York, it likely involves research and development or support services...
- <p>This contract was awarded by the U.S. Department of Health and Human Services (HHS) to Provid Pharmaceuticals Inc., a small business, for the development of anticancer agents under the Small Business Innovation Research (SBIR) Program Phase I. The contract has a firm fixed-price of $149,558.00 and a completion date of March 31, 2009. The contract was set aside for total small business participation.</p>
- This is a federal contract award from the Department of Health and Human Services (HHS) to Buffalo Biolabs, LLC, a small business located in Buffalo, NY. The contract is for a Small Business Innovation Research (SBIR) Program Phase I research project in the biomedical field, with a total contract value of $148,725.00 and a completion date of March 31, 2010. The contract is a Firm Fixed Price Definitive Contract, which indicates the scope of work and deliverables were pre-determined. As a SBIR...
- <p>This is a Small Business Innovation Research (SBIR) Program Phase I contract awarded by the U.S. Department of Health and Human Services (HHS) to Buffalo Biolabs, LLC, a small business located in Buffalo, New York. The contract is for basic physical sciences research with a firm fixed price of $149,987 and a period of performance ending on March 31, 2010. The contract was awarded on September 30, 2009 and has a total small business set-aside designation.</p>
- This is a Cost Plus Fixed Fee contract awarded by the National Cancer Institute, a civilian agency, to Buffalo Biolabs, LLC, a small business, for the development of anticancer agents under the Small Business Innovation Research (SBIR) program. The award amount is $1,496,764.00 and the period of performance is until October 31, 2014. The contract is a Phase II SBIR action, which indicates it is for the continued development and testing of a promising technology that was previously funded under a...
- The U.S. government agency awarded a Small Business Innovation Research (SBIR) Program Phase I action contract to Aphios Corp, a minority-owned for-profit organization, for the development of anticancer agents. The fixed-price contract, valued at $149,558.00, was awarded on September 30, 2008, with a completion date of May 31, 2009. The contract was a result of a request for proposal (RFP) titled "DEVELOPMENT OF ANTICANCER AGENTS" and was assigned the solicitation number...
- This is a federal contract award from the National Cancer Institute, a civilian agency, to Hemoshear Therapeutics, LLC, a small business. The contract, valued at $1,985,657.32, is for SBIR Phase II work titled "Validation of the HemoShear Tumor Microenvironment System for Drug Discovery and Development." The contract is a Cost Plus Fixed Fee Definitive Contract and was awarded on September 21, 2015, with an ultimate completion date of April 30, 2019. The contract was set aside for...
- This is a federal contract awarded by an unspecified U.S. government agency to Nanoparticle Biochem, Inc., a small business, for a Small Business Innovation Research (SBIR) Program Phase I action. The contract has a Definitive Contract type, Firm Fixed Price pricing, and a Ceiling Value of $135,973.00. The contract is for Biomedical (Basic) research and was awarded on September 30, 2008, with an Ultimate Completion Date of March 30, 2009. The place of performance is Columbia, MO 65201, USA. This...
- This contract was awarded by the U.S. Department of Health and Human Services (HHS) to Gene Segues, Inc., a small business, for the development of anticancer agents under the Small Business Innovation Research (SBIR) program. The total ceiling value of the Firm Fixed Price contract is $185,073.00, and the period of performance runs from September 30, 2008 to March 31, 2009. The contract was set aside for small businesses. The award reflects Gene Segues, Inc.'s expertise in the field of cancer...